[{"id":"d24f8d9a-9e2f-4861-9181-2b0a6f6b5ba4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05556798","created_at":"2022-09-27T14:04:44.698Z","updated_at":"2024-07-02T16:35:05.385Z","phase":"Phase 1","brief_title":"A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment","source_id_and_acronym":"NCT05556798","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/04/2022","start_date":" 10/04/2022","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-07"},{"id":"4d7f225a-7afa-4e5a-a31b-96fb1c3ee410","acronym":"","url":"https://clinicaltrials.gov/study/NCT04195399","created_at":"2021-01-18T20:26:44.866Z","updated_at":"2024-07-02T16:35:16.137Z","phase":"Phase 2","brief_title":"A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery","source_id_and_acronym":"NCT04195399","lead_sponsor":"Children's Oncology Group","biomarkers":" CD8 • CTNNB1 • APC • CD4","pipe":" | ","alterations":" APC mutation","tags":["CD8 • CTNNB1 • APC • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ogsiveo (nirogacestat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-06"},{"id":"2edaec8d-eed2-4793-8244-dd50e749a2b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05573802","created_at":"2022-10-10T14:05:36.991Z","updated_at":"2025-02-25T13:13:10.445Z","phase":"Phase 1/2","brief_title":"A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma","source_id_and_acronym":"NCT05573802","lead_sponsor":"Hellenic Society of Hematology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • dexamethasone • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2023-10-24"},{"id":"35ab7548-637e-4229-8bfc-9998c89fa4e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01653470","created_at":"2021-01-18T07:07:38.583Z","updated_at":"2024-07-02T16:36:50.836Z","phase":"Phase 1","brief_title":"Study to Evaluate Safety \u0026 Tolerability of BMS-906024 in Combination With Chemotherapy \u0026 to Define DLTs \u0026 MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors","source_id_and_acronym":"NCT01653470","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" HES1","pipe":" | ","alterations":" NOTCH mutation","tags":["HES1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOTCH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • 5-fluorouracil • irinotecan • leucovorin calcium • AL101 • fluorouracil topical"],"overall_status":"Completed","enrollment":" Enrollment 141","initiation":"Initiation: 10/12/2012","start_date":" 10/12/2012","primary_txt":" Primary completion: 05/03/2017","primary_completion_date":" 05/03/2017","study_txt":" Completion: 05/08/2017","study_completion_date":" 05/08/2017","last_update_posted":"2020-01-28"},{"id":"80dea25b-d9ea-4ed6-b053-ee4a0189b047","acronym":"","url":"https://clinicaltrials.gov/study/NCT00878189","created_at":"2021-01-18T03:21:27.001Z","updated_at":"2024-07-02T16:36:53.866Z","phase":"Phase 1","brief_title":"A Trial In Patients With Advanced Cancer And Leukemia","source_id_and_acronym":"NCT00878189","lead_sponsor":"Pfizer","biomarkers":" NOTCH1 • NICD • HES4","pipe":" | ","alterations":" NOTCH1 expression","tags":["NOTCH1 • NICD • HES4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOTCH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ogsiveo (nirogacestat)"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 06/25/2009","start_date":" 06/25/2009","primary_txt":" Primary completion: 01/10/2013","primary_completion_date":" 01/10/2013","study_txt":" Completion: 11/22/2016","study_completion_date":" 11/22/2016","last_update_posted":"2019-11-12"},{"id":"ffc3eeaf-0c0b-4248-ac40-a4e3ffc99220","acronym":"","url":"https://clinicaltrials.gov/study/NCT02518113","created_at":"2021-01-18T12:10:07.428Z","updated_at":"2024-07-02T16:36:55.784Z","phase":"Phase 1b","brief_title":"A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL","source_id_and_acronym":"NCT02518113","lead_sponsor":"Eli Lilly and Company","biomarkers":" NOTCH1 • FBXW7","pipe":" | ","alterations":" FBXW7 mutation • NOTCH mutation","tags":["NOTCH1 • FBXW7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FBXW7 mutation • NOTCH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • crenigacestat (LY3039478)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 01/15/2018","primary_completion_date":" 01/15/2018","study_txt":" Completion: 01/15/2018","study_completion_date":" 01/15/2018","last_update_posted":"2019-09-11"},{"id":"b9bd979a-e4a6-4642-b91a-5eb322a28447","acronym":"","url":"https://clinicaltrials.gov/study/NCT00756717","created_at":"2021-01-18T02:51:35.116Z","updated_at":"2025-02-25T15:58:33.556Z","phase":"Phase 4","brief_title":"Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer","source_id_and_acronym":"NCT00756717","lead_sponsor":"Loyola University","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • MK-0752"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 02/14/2008","start_date":" 02/14/2008","primary_txt":" Primary completion: 12/21/2011","primary_completion_date":" 12/21/2011","study_txt":" Completion: 12/21/2011","study_completion_date":" 12/21/2011","last_update_posted":"2019-09-04"},{"id":"a8b7acf7-bd10-4912-aace-f566fbaf1082","acronym":"RHEA","url":"https://clinicaltrials.gov/study/NCT02338531","created_at":"2021-01-18T11:06:35.638Z","updated_at":"2024-07-02T16:37:32.462Z","phase":"Phase 2","brief_title":"Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer","source_id_and_acronym":"NCT02338531 - RHEA","lead_sponsor":"Jules Bordet Institute","biomarkers":" HER-2 • HES4","pipe":"","alterations":" ","tags":["HER-2 • HES4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ogsiveo (nirogacestat)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2016-04-29"}]